ERBB2 and cancer: Moreover, CD16(Nb)/IL-15/HER2(scFv) TriKE could significantly activate the NK cells and inhibit the proliferation of HER2+ cancer cells in vitro (SKOV3 and SKBR3 cells) and in vivo (xenograft NGS mice models) (111).